465 reports of this reaction
2.4% of all VIGABATRIN reports
#7 most reported adverse reaction
DRUG WITHDRAWAL CONVULSIONS is the #7 most commonly reported adverse reaction for VIGABATRIN, manufactured by Lundbeck Pharmaceuticals LLC. There are 465 FDA adverse event reports linking VIGABATRIN to DRUG WITHDRAWAL CONVULSIONS. This represents approximately 2.4% of all 19,478 adverse event reports for this drug.
Patients taking VIGABATRIN who experience drug withdrawal convulsions should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG WITHDRAWAL CONVULSIONS is a less commonly reported adverse event for VIGABATRIN, but still significant enough to appear in the safety profile.
In addition to drug withdrawal convulsions, the following adverse reactions have been reported for VIGABATRIN:
The following drugs have also been linked to drug withdrawal convulsions in FDA adverse event reports:
DRUG WITHDRAWAL CONVULSIONS has been reported as an adverse event in 465 FDA reports for VIGABATRIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG WITHDRAWAL CONVULSIONS accounts for approximately 2.4% of all adverse event reports for VIGABATRIN, making it a notable side effect.
If you experience drug withdrawal convulsions while taking VIGABATRIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.